# Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists

> **NCT00670930** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 36 (actual)

## Conditions studied

- Allergic Asthma

## Interventions

- **DRUG:** omalizumab at a dose of 0.016mg/kg/IU/mL
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00670930
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2013-01-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00670930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00670930, "Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00670930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*